Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity trends in the pharmaceutical industry. The report, titled “USPTO Drug Patent and Exclusivity Study Report,” …
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. The generic ingredient in VEKLURY is remdesivir…
This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs are: TARO HIKMA HARROW EYE NOVITIUM PHARMA AMNEAL BAU…
Which pharmaceutical companies have the most suspension dosed drugs? Read Post »
The 505(b)(2) regulatory pathway provides an attractive avenue for drug developers to bring new products to market by leveraging existing data on approved drugs. This pathway allows modifications and improvements to be made to existing drugs, while pot…
Leveraging 505(b)(2) to Innovate Beyond Existing Drug Patents Read Post »
The development of injectable formulations is a complex and critical aspect of pharmaceutical manufacturing. Excipients, the inactive ingredients in these formulations, play a pivotal role in ensuring the stability, efficacy, and safety of the final pr…
Excipient Use in Injectable Formulations: Best Practices Read Post »
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPat…
Drug Patent Expirations for the Week of June 23, 2024 Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obta…
Which pharmaceutical companies have the most SPCs in Italy? Read Post »
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPat…
Drug Patent Expirations for the Week of June 23, 2024 Read Post »
Get new actionable insights and updates from BiotechBlog
